HLS Historical Income Statement
| HLS Stock | CAD 4.65 0.05 1.06% |
Historical analysis of HLS Therapeutics income statement accounts such as Total Revenue of 55.7 M or Gross Profit of 24.4 M can show how well HLS Therapeutics performed in making a profits. Evaluating HLS Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of HLS Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining HLS Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether HLS Therapeutics is a good buy for the upcoming year.
HLS |
About HLS Income Statement Analysis
HLS Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to HLS Therapeutics shareholders. The income statement also shows HLS investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
HLS Therapeutics Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Revenue
Total revenue comprises all receipts HLS Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of HLS Therapeutics minus its cost of goods sold. It is profit before HLS Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from HLS Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into HLS Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HLS Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, HLS Therapeutics' Selling And Marketing Expenses is very stable compared to the past year. As of the 24th of March 2025, Reconciled Depreciation is likely to grow to about 25 M, while Total Revenue is likely to drop about 55.7 M.
| 2022 | 2023 | 2024 | 2025 (projected) | Total Revenue | 61.5M | 63.1M | 56.6M | 55.7M | Interest Expense | 7.3M | 8.7M | 10.1M | 10.6M |
HLS Therapeutics income statement Correlations
Click cells to compare fundamentals
HLS Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
HLS Therapeutics income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 33.2M | 30.3M | 34.4M | 31.9M | 36.7M | 38.6M | |
| Interest Expense | 6.3M | 7.0M | 7.3M | 8.7M | 10.1M | 10.6M | |
| Total Revenue | 56.1M | 60.0M | 61.5M | 63.1M | 56.6M | 55.7M | |
| Gross Profit | 52.5M | 56.0M | 56.5M | 55.5M | 47.6M | 24.4M | |
| Other Operating Expenses | 68.2M | 66.3M | 75.0M | 73.4M | 66.1M | 51.0M | |
| Operating Income | (11.3M) | (6.2M) | (13.4M) | (10.0M) | (7.7M) | (7.3M) | |
| Ebit | (11.3M) | (6.2M) | (13.4M) | (10.0M) | (9.0M) | (8.5M) | |
| Ebitda | 21.9M | 24.0M | 21.0M | 21.9M | 25.2M | 15.1M | |
| Cost Of Revenue | 3.6M | 4.0M | 5.0M | 7.6M | 9.0M | 8.5M | |
| Total Operating Expenses | 64.6M | 62.3M | 70.0M | 65.8M | 64.3M | 67.5M | |
| Income Before Tax | (16.3M) | (11.8M) | (23.7M) | (27.8M) | (15.6M) | (14.8M) | |
| Total Other Income Expense Net | (5.0M) | (5.6M) | (10.3M) | (9.1M) | 1.9M | 2.0M | |
| Net Income | (15.3M) | (13.1M) | (23.6M) | (27.5M) | (19.7M) | (18.7M) | |
| Income Tax Expense | (968K) | 1.3M | (124K) | (272K) | (244.8K) | (232.6K) | |
| Selling General Administrative | 18.5M | 17.4M | 17.7M | 8.4M | 26.9M | 28.3M | |
| Tax Provision | (968K) | 1.3M | (124K) | (272K) | 4.1M | 4.3M | |
| Selling And Marketing Expenses | 12.9M | 14.7M | 17.8M | 19.9M | 22.9M | 24.0M | |
| Net Income From Continuing Ops | (15.3M) | (13.1M) | (23.6M) | (27.5M) | (19.7M) | (20.6M) | |
| Net Income Applicable To Common Shares | (19.6M) | (15.3M) | (13.1M) | (23.6M) | (21.2M) | (22.3M) | |
| Net Interest Income | (6.0M) | (6.9M) | (7.3M) | (8.4M) | (9.8M) | (10.3M) | |
| Interest Income | 322K | 44K | 57K | 350K | 319K | 212.4K | |
| Reconciled Depreciation | 33.2M | 30.3M | 34.4M | 31.9M | 22.7M | 25.0M |
Pair Trading with HLS Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with HLS Stock
Moving against HLS Stock
The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLS Stock
HLS Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to HLS Therapeutics shareholders. The income statement also shows HLS investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).